Hi Shombra, . Thankyou for that information, very enlightening .
From putting both your info and mine together (company released data), we can see that the trial was flying along, as of 31st October 2023 there had been 34 patients dosed with 25 available for evaluation.
Then in April 2024 (they had a typo 2004), there were 47 patients dosed with 40 able to be evaluated.
Wow thats 15 more patients available for evaluation in 6 months, (including the Christmas break).
That is remarkable speed for a clinical trial as patients can only be scanned at the 42 day mark.
Like you I am enthusiastically waiting for the next update as it is sure to include some of the higher dosed cohort and this will surely have a higher number of overall responses, (including SD, CR & PR).
DYOR opinion only
IMU Price at posting:
3.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)